Participant flow14

How many started, completed or left each group, period by period.

1 to 14 of 14

Period	Milestone	Group	Participants
Double-blind Treatment Period	STARTED	Benralizumab 30 mg	54
Double-blind Treatment Period	STARTED	Placebo	45
Double-blind Treatment Period	Treated	Benralizumab 30 mg	54
Double-blind Treatment Period	Treated	Placebo	45
Double-blind Treatment Period	COMPLETED	Benralizumab 30 mg	42
Double-blind Treatment Period	COMPLETED	Placebo	42
Double-blind Treatment Period	NOT COMPLETED	Benralizumab 30 mg	12
Double-blind Treatment Period	NOT COMPLETED	Placebo	3
Open-label Extension Period	STARTED	Benralizumab 30 mg	38
Open-label Extension Period	STARTED	Placebo	40
Open-label Extension Period	COMPLETED	Benralizumab 30 mg	38
Open-label Extension Period	COMPLETED	Placebo	39
Open-label Extension Period	NOT COMPLETED	Benralizumab 30 mg	0
Open-label Extension Period	NOT COMPLETED	Placebo	1

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05006573/flow